Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (2s)-n-((1s)-1-benzyl-2-(((1s)-3-methyl-1-(((2r)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2s)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide
2. Kyprolis
3. Pr-171
4. Pr171
1. 868540-17-4
2. Kyprolis
3. Carfilzomib (pr-171)
4. Pr-171
5. Carfilzomib (pr171)
6. Unii-72x6e3j5ar
7. Nsc-758252
8. 72x6e3j5ar
9. Chembl451887
10. Chebi:65347
11. Ncgc00249613-01
12. Dsstox_cid_28616
13. Dsstox_rid_82886
14. Dsstox_gsid_48690
15. (2s)-4-methyl-n-[(2s)-1-[[(2s)-4-methyl-1-[(2r)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2s)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
16. (2s)-n-((1s)-1-benzyl-2-(((1s)-3-methyl-1-(((2r)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2s)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide
17. (alphas)-alpha-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-l-leucyl-n-[(1s)-3-methyl-1-[[(2r)-2-methyl-2-oxiranyl]carbonyl]butyl]-l-phenylalaninamide
18. (s)-4-methyl-n-((s)-1-(((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
19. N-{(2s)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-l-leucyl-n-{(2s)-4-methyl-1-[(2r)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-l-phenylalaninamide
20. (s)-4-methyl-n-((s)-1-((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
21. Carfilzomib [usan]
22. Cas-868540-17-4
23. Carfilzomib [usan:inn]
24. Mfcd11040997
25. Kyprolis (tn)
26. Carfilzomib; Pr171
27. Carfilzomib [mi]
28. Carfilzomib [inn]
29. Carfilzomib [jan]
30. Carfilzomib [vandf]
31. Schembl85165
32. Carfilzomib [who-dd]
33. Mls006011102
34. Carfilzomib (jan/usan/inn)
35. Gtpl7420
36. Dtxsid4048690
37. Amy4357
38. Carfilzomib [orange Book]
39. Ex-a2037
40. Ono-7057
41. Tox21_113079
42. Bdbm50277889
43. Nsc756640
44. Nsc758252
45. S2853
46. Zinc49841054
47. Akos025401910
48. Tox21_113079_1
49. Ccg-270405
50. Cs-0984
51. Cs-w004540
52. Db08889
53. Nsc 758252
54. Nsc-756640
55. Ncgc00249613-02
56. Ncgc00249613-03
57. Ncgc00249613-08
58. Ncgc00249613-11
59. Ncgc00249613-13
60. Ac-27051
61. As-17059
62. Hy-10455
63. Smr004660024
64. Sw218090-2
65. D08880
66. Ab01565867_02
67. Sr-01000941582
68. J-501773
69. Sr-01000941582-1
70. Q15366934
71. (alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-l-phe Nylalaninamide
72. (s)-4-methyl-n-((s)-1-((s)-4-methyl-1-((r)-2- Methyloxiran-2-yl)-1 -oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
73. L-phenylalaninamide, (.alpha.s)-.alpha.-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-
74. L-phenylalaninamide, (alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-
Molecular Weight | 719.9 g/mol |
---|---|
Molecular Formula | C40H57N5O7 |
XLogP3 | 4.7 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 20 |
Exact Mass | 719.42579917 g/mol |
Monoisotopic Mass | 719.42579917 g/mol |
Topological Polar Surface Area | 159 Ų |
Heavy Atom Count | 52 |
Formal Charge | 0 |
Complexity | 1180 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 5 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Kyprolis |
PubMed Health | Carfilzomib (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | KYPROLIS (carfilzomib) for Injection is an antineoplastic agent available for intravenous use only. KYPROLIS is a sterile, white to off-white lyophilized powder and is available as a single-use vial. Each vial of KYPROLIS contains 60mg of carfilzom... |
Active Ingredient | Carfilzomib |
Dosage Form | Powder |
Route | Intravenous |
Strength | 60mg/vial |
Market Status | Prescription |
Company | Onyx Pharms |
2 of 2 | |
---|---|
Drug Name | Kyprolis |
PubMed Health | Carfilzomib (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | KYPROLIS (carfilzomib) for Injection is an antineoplastic agent available for intravenous use only. KYPROLIS is a sterile, white to off-white lyophilized powder and is available as a single-use vial. Each vial of KYPROLIS contains 60mg of carfilzom... |
Active Ingredient | Carfilzomib |
Dosage Form | Powder |
Route | Intravenous |
Strength | 60mg/vial |
Market Status | Prescription |
Company | Onyx Pharms |
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
FDA Label
Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Treatment of Multiple Myeloma
Treatment of acute lymphoblastic leukaemia
Intravenous carfilzomib administration resulted in suppression of proteasome chymotrypsin-like activity when measured in blood 1 hour after the first dose. On Day 1 of Cycle 1, proteasome inhibition in peripheral blood mononuclear cells (PBMCs) ranged from 79% to 89% at 15 mg/m2, and from 82% to 83% at 20 mg/m2. In addition, carfilzomib administration resulted in inhibition of the LMP2 and MECL1 subunits of the immunoproteasome ranging from 26% to 32% and 41% to 49%, respectively, at 20 mg/m2. Proteasome inhibition was maintained for 48 hours following the first dose of carfilzomib for each week of dosing. Resistance against carfilzomib has been observed and although the mechanism has not been confirmed, it is thought that up-regulation of P-glycoprotein may be a contributing factor. Furthermore, studies suggest that carfilzomib is more potent than bortezomib.
L01XX45
L01XX45
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01X - Other antineoplastic agents
L01XG - Proteasome inhibitors
L01XG02 - Carfilzomib
Absorption
Cmax, single IV dose of 27 mg/m^2 = 4232 ng/mL; AUC, single IV dose of 27 mg/m^2 = 379 nghr/mL; Carfilzomib does not accumulation in the systemic. At doses between 20 and 36 mg/m2, there was a dose-dependent increase in exposure.
Volume of Distribution
Vd, steady state, 20 mg/m^2 = 28 L
Clearance
Systemic clearance = 151 - 263 L/hour. As this value exceeds hepatic blood flow, it suggests that carfilozmib is cleared extrahepatically.
Carfilzomib was rapidly and extensively metabolized by the liver. The predominant metabolites were the peptide fragments and the diol of carfilzomib which suggests that the main metabolic pathways are peptidase cleavage and epoxide hydrolysis. The cytochrome P450 enzyme system is minimally involved in the metabolism of carfilzomib. All metabolites are inactive.
Following intravenous administration of doses 15 mg/m^2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of 1 hour on Day 1 of Cycle 1.
Carfilzomib is made up of four modified peptides and acts as a proteasome inhibitor. Carfilzomib irreversibly and selectively binds to N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. This 20S core has 3 catalytic active sites: the chymotrypsin, trypsin, and caspase-like sites. Inhibition of the chymotrypsin-like site by carfilzomib (5 and 5i subunits) is the most effective target in decreasing cellular proliferation, ultimately resulting in cell cycle arrest and apoptosis of cancerous cells. At higher doses, carfilzomib will inhibit the trypsin-and capase-like sites.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-06-06
Valid Till : 2025-07-07
Written Confirmation Number : WC-0039
Address of the Firm : Unit-I, Plot Nos.137, 138, 145 & 146, Sri Venkateswara Co- Operative Industrial ...
Date of Issue : 2022-09-30
Valid Till : 2025-09-15
Written Confirmation Number : WC-0115A3
Address of the Firm : D-35, Industrial Area, Kalyani, Dist Nadia-741 235, West Bengal
Date of Issue : 2023-07-03
Valid Till : 2025-07-02
Written Confirmation Number : WC-0213
Address of the Firm : Plot No.21, Jawaharlal Nehru Pharma City, Parawada MandaI, Visakhapatnam, Visakh...
Date of Issue : 2022-09-02
Valid Till : 2025-05-05
Written Confirmation Number : WC-0349
Address of the Firm : MIs. MSN Laboratories Private Limited, Unit-II, sv. No, 50, Kardanur (Village), ...
Date of Issue : 2020-07-23
Valid Till : 2023-05-11
Written Confirmation Number : WC-0273
Address of the Firm : Plot No. 34A, J.N.Pharma City, Thanam (V), Parawada (M), Vishakhapatnam-District...
Date of Issue : 2020-03-18
Valid Till : 2020-05-11
Written Confirmation Number : WC-0273A7
Address of the Firm : Plot No. 34A, J.N.Pharma City, Thanam (V), Parawada (M), Vishakhapatnam-District...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
CHMP issues positive opinion for second indication for Sarclisa in combination with carfilzomib and dexamethasone for adult patients with multiple myeloma who have received at least one prior therapy.
Lead Product(s): Isatuximab,Carfilzomib
Therapeutic Area: Oncology Brand Name: Sarclisa
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 26, 2021
Lead Product(s) : Isatuximab,Carfilzomib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CHMP issues positive opinion for second indication for Sarclisa in combination with carfilzomib and dexamethasone for adult patients with multiple myeloma who have received at least one prior therapy.
Product Name : Sarclisa
Product Type : Antibody
Upfront Cash : Inapplicable
February 26, 2021
Details:
Addition of Sarclisa significantly reduced the risk of disease progression or death compared to carfilzomib and dexamethasone alone.
Lead Product(s): Isatuximab,Carfilzomib
Therapeutic Area: Oncology Brand Name: Sarclisa
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 05, 2020
Lead Product(s) : Isatuximab,Carfilzomib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanofi's Sarclisa Cuts Death Risk In Mutiple Myeloma
Details : Addition of Sarclisa significantly reduced the risk of disease progression or death compared to carfilzomib and dexamethasone alone.
Product Name : Sarclisa
Product Type : Antibody
Upfront Cash : Inapplicable
December 05, 2020
Details:
Sarclisa added to carfilzomib and dexamethasone (Sarclisa combination) reduced risk of disease progression or death by 47% versus standard of care carfilzomib and dexamethasone (Kd) alone.
Lead Product(s): Isatuximab,Carfilzomib
Therapeutic Area: Oncology Brand Name: Sarclisa
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 06, 2020
Lead Product(s) : Isatuximab,Carfilzomib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sarclisa added to carfilzomib and dexamethasone (Sarclisa combination) reduced risk of disease progression or death by 47% versus standard of care carfilzomib and dexamethasone (Kd) alone.
Product Name : Sarclisa
Product Type : Antibody
Upfront Cash : Inapplicable
February 06, 2020
Details:
Kyprolis-Generic (carfilzomib) is a proteasome inhibitor, small molecule drug candidate, which is indicated for the treatment of patients with relapsed or refractory multiple myeloma as monotherapy or in combination with dexamethasone or with lenalidomide plus dexamethasone.
Lead Product(s): Carfilzomib,Dexamethasone
Therapeutic Area: Oncology Brand Name: Kyprolis-Generic
Study Phase: Approved FDFProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 16, 2021
Lead Product(s) : Carfilzomib,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Kyprolis-Generic (carfilzomib) is a proteasome inhibitor, small molecule drug candidate, which is indicated for the treatment of patients with relapsed or refractory multiple myeloma as monotherapy or in combination with dexamethasone or with lenalidomid...
Product Name : Kyprolis-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
June 16, 2021
Details:
TTI-622 is a fusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumors.
Lead Product(s): Maplirpacept,Carfilzomib
Therapeutic Area: Oncology Brand Name: TTI-622
Study Phase: Phase IProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 28, 2021
Lead Product(s) : Maplirpacept,Carfilzomib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TTI-622 is a fusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumors.
Product Name : TTI-622
Product Type : Protein
Upfront Cash : Inapplicable
April 28, 2021
Details:
U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS® (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX® (daratumumab) plus dexamethasone (DKd) in two dosing regimens.
Lead Product(s): Carfilzomib,Daratumumab
Therapeutic Area: Oncology Brand Name: Kyprolis
Study Phase: Approved FDFProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 20, 2020
Lead Product(s) : Carfilzomib,Daratumumab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Carfilzomib and Daratumumab with Dexamethasone for Multiple Myeloma
Details : U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS® (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX® (daratumumab) plus dexamethasone (DKd) in two dosing regimens.
Product Name : Kyprolis
Product Type : Peptide
Upfront Cash : Inapplicable
August 20, 2020
Details:
Data presented in the ePoster demonstrates that the pelareorep-carfilzomib combination treatment results in selective replication of pelareorep in cancer cells and beneficial induction of an inflamed tumor environment associated with clinical responses.
Lead Product(s): Pelareorep,Carfilzomib
Therapeutic Area: Oncology Brand Name: Reolysin
Study Phase: Phase IProduct Type: Microorganism
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 29, 2020
Lead Product(s) : Pelareorep,Carfilzomib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtu...
Details : Data presented in the ePoster demonstrates that the pelareorep-carfilzomib combination treatment results in selective replication of pelareorep in cancer cells and beneficial induction of an inflamed tumor environment associated with clinical responses.
Product Name : Reolysin
Product Type : Microorganism
Upfront Cash : Inapplicable
May 29, 2020
Details:
Clinical response was associated with tumor-specific replication, PD-L1 upregulation, and CD8+ cell recruitment in multiple myeloma patients treated with pelareorep and carfilzomib.
Lead Product(s): Pelareorep,Carfilzomib
Therapeutic Area: Oncology Brand Name: Reolysin
Study Phase: Phase IProduct Type: Microorganism
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 14, 2020
Lead Product(s) : Pelareorep,Carfilzomib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Oncolytics Biotech® Announces Publication of Abstracts at the 2020 American Society of Clinical O...
Details : Clinical response was associated with tumor-specific replication, PD-L1 upregulation, and CD8+ cell recruitment in multiple myeloma patients treated with pelareorep and carfilzomib.
Product Name : Reolysin
Product Type : Microorganism
Upfront Cash : Inapplicable
May 14, 2020
Regulatory Info :
Registration Country : Sweden
Brand Name : Kyprolis
Dosage Form : POWDER FOR SOLUTION FOR INFUSION
Dosage Strength : 60 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Norway
Brand Name : Kyprolis
Dosage Form : Powder for infusion fluid, resolution
Dosage Strength : 10 mg
Packaging : Hood glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Kyprolis
Dosage Form : Powder for infusion fluid, resolution
Dosage Strength : 30 mg
Packaging : Hood glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Kyprolis
Dosage Form : Powder for infusion fluid, resolution
Dosage Strength : 60 mg
Packaging : Hood glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Kyprolis
Dosage Form : Dry Sub
Dosage Strength : 60mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Kyprolis
Dosage Form : Dry Sub
Dosage Strength : 10mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Kyprolis
Dosage Form : Dry Sub
Dosage Strength : 30mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
33
PharmaCompass offers a list of Carfilzomib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Carfilzomib manufacturer or Carfilzomib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Carfilzomib manufacturer or Carfilzomib supplier.
PharmaCompass also assists you with knowing the Carfilzomib API Price utilized in the formulation of products. Carfilzomib API Price is not always fixed or binding as the Carfilzomib Price is obtained through a variety of data sources. The Carfilzomib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Carfilzomib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Carfilzomib, including repackagers and relabelers. The FDA regulates Carfilzomib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Carfilzomib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Carfilzomib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Carfilzomib supplier is an individual or a company that provides Carfilzomib active pharmaceutical ingredient (API) or Carfilzomib finished formulations upon request. The Carfilzomib suppliers may include Carfilzomib API manufacturers, exporters, distributors and traders.
click here to find a list of Carfilzomib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Carfilzomib DMF (Drug Master File) is a document detailing the whole manufacturing process of Carfilzomib active pharmaceutical ingredient (API) in detail. Different forms of Carfilzomib DMFs exist exist since differing nations have different regulations, such as Carfilzomib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Carfilzomib DMF submitted to regulatory agencies in the US is known as a USDMF. Carfilzomib USDMF includes data on Carfilzomib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Carfilzomib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Carfilzomib suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Carfilzomib Drug Master File in Korea (Carfilzomib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Carfilzomib. The MFDS reviews the Carfilzomib KDMF as part of the drug registration process and uses the information provided in the Carfilzomib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Carfilzomib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Carfilzomib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Carfilzomib suppliers with KDMF on PharmaCompass.
A Carfilzomib written confirmation (Carfilzomib WC) is an official document issued by a regulatory agency to a Carfilzomib manufacturer, verifying that the manufacturing facility of a Carfilzomib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Carfilzomib APIs or Carfilzomib finished pharmaceutical products to another nation, regulatory agencies frequently require a Carfilzomib WC (written confirmation) as part of the regulatory process.
click here to find a list of Carfilzomib suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Carfilzomib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Carfilzomib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Carfilzomib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Carfilzomib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Carfilzomib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Carfilzomib suppliers with NDC on PharmaCompass.
Carfilzomib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Carfilzomib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Carfilzomib GMP manufacturer or Carfilzomib GMP API supplier for your needs.
A Carfilzomib CoA (Certificate of Analysis) is a formal document that attests to Carfilzomib's compliance with Carfilzomib specifications and serves as a tool for batch-level quality control.
Carfilzomib CoA mostly includes findings from lab analyses of a specific batch. For each Carfilzomib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Carfilzomib may be tested according to a variety of international standards, such as European Pharmacopoeia (Carfilzomib EP), Carfilzomib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Carfilzomib USP).